BioSpace

The race for access: How the FAIR Act could reclaim U.S. biotech leadership

In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster.

Por BioSpace

1 minuto de lectura
Compartir
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
The race for access: How the FAIR Act could reclaim U.S. biotech leadership

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas